Payment overview · 2025
General Payments
$2,685.26
15 reported records · 6 companies
Healthcare provider profile · identity verified
Anant Jeet, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LORAIN, OH · NPI 1790759900
Verified facts
What the public records show
CMS Open Payments records show Anant Jeet, MD received $2,685.26 in general payments during 2025 across 15 reported records.
Abbott Laboratories accounted for 84.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,263.22 | 84.3% | 10 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $114.88 | 4.3% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $113.85 | 4.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $104.43 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.38 | 1.7% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $42.50 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,100.00 | 2 |
| Food and Beverage | $542.76 | 12 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $2,263.22 | 10 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $114.88 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $113.85 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $104.43 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.38 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $42.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1469 | 348 |
| Metformin Hcl | Metformin Hcl | 764 | 194 |
| Trulicity | Dulaglutide | 754 | 144 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 677 | 185 |
| Ozempic | Semaglutide | 360 | 78 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 344 | 116 |
| Pioglitazone Hcl | Pioglitazone Hcl | 315 | 75 |
| Mounjaro | Tirzepatide | 304 | 69 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 298 | 80 |
| Glimepiride | Glimepiride | 287 | 72 |
| Methimazole | Methimazole | 223 | 49 |
| Januvia | Sitagliptin Phosphate | 217 | 49 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 217 | 53 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 211 | 57 |
| Humalog Kwikpen U-100 | Insulin Lispro | 207 | 73 |
| Metformin Hcl Er | Metformin Hcl | 184 | 54 |
| Synthroid | Levothyroxine Sodium | 183 | 48 |
| Gabapentin | Gabapentin | 177 | 35 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 176 | 67 |
| Jardiance | Empagliflozin | 167 | 39 |
| Lisinopril | Lisinopril | 160 | 37 |
| Novolog Flexpen | Insulin Aspart | 157 | 45 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 147 | 50 |
| Humalog | Insulin Lispro | 145 | 44 |
| Insulin Lispro | Insulin Lispro | 139 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 124 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 98 | 33 |
| Farxiga | Dapagliflozin Propanediol | 95 | 29 |
| Novolog | Insulin Aspart | 94 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 86 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 22 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 75 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 73 | 18 |
| Rybelsus | Semaglutide | 72 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 68 | 24 |
| Ezetimibe | Ezetimibe | 67 | 15 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 65 | 27 |
| Unifine Pentips Plus | Pen Needle, Diabetic | 65 | 25 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 64 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 63 | 29 |
| Hydrocortisone | Hydrocortisone | 63 | suppressed |
| Levemir Flexpen | Insulin Detemir | 63 | 21 |
| Pregabalin | Pregabalin | 62 | 12 |
| Glycopyrrolate | Glycopyrrolate | 60 | 14 |
| Droplet Pen Needle | Pen Needle, Diabetic | 59 | 30 |
| Single Use Swab | Alcohol Antiseptic Pads | 56 | 23 |
| Simvastatin | Simvastatin | 55 | 14 |
| Novofine 32 | Pen Needle, Diabetic | 54 | 18 |
| Omeprazole | Omeprazole | 54 | 11 |
| Losartan Potassium | Losartan Potassium | 52 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 52 | 12 |
| Invokana | Canagliflozin | 49 | suppressed |
| Potassium Chloride | Potassium Chloride | 49 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 48 | suppressed |
| Admelog Solostar | Insulin Lispro | 46 | 13 |
| Furosemide | Furosemide | 42 | 11 |
| Glipizide | Glipizide | 41 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 41 | 16 |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 37 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 31 | 14 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 28 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Testosterone | Testosterone | 28 | 11 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 25 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Cabergoline | Cabergoline | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Propylthiouracil | Propylthiouracil | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Easy Touch Safety Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,685.26 · 15 records | Abbott Laboratories | AFREZZA, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Omnipod, Yorvipath, t:slim X2 Insulin Pump with Control-IQ | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error